Position in SLGL
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$428,899
New position
Shares Held
5,785
first reported quarter
Ownership
0.177%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#14
of 24 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026NAVELLIER & ASSOCIATES INC holds $13,792,589 across 6 Biotechnology names. SLGL ranks #5 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
7,257 | $6,732,826 | |
| 2 | AUPH |
Aurinia Pharmaceuticals Inc.
|
257,142 | $4,363,699 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
29,290 | $1,609,192 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
19,696 | $516,429 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
This page
|
5,785 | $428,899 | |
| 6 | ELDN |
Eledon Pharmaceuticals, Inc.
|
35,925 | $141,544 |
All Filings in SLGL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $428,899 | 5,785 | Shares | Sole | 2026-08-04 | |
| No filing history on record for this holder in this stock. | ||||||